{"id":14728,"date":"2020-09-10T11:52:31","date_gmt":"2020-09-09T22:52:31","guid":{"rendered":"https:\/\/clladvocates.nz\/?p=14728"},"modified":"2020-09-10T11:52:31","modified_gmt":"2020-09-09T22:52:31","slug":"which-drug-therapy-for-cll-time-limited-or-continuous","status":"publish","type":"post","link":"https:\/\/clladvocates.nz\/?p=14728","title":{"rendered":"Which Drug Therapy for CLL, Time-Limited or Continuous?"},"content":{"rendered":"

[vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”2″ top_padding=”3″ bottom_padding=”3″ overlay_alpha=”50″ gutter_size=”3″ column_width_percent=”100″ shift_y=”0″ z_index=”0″][vc_column column_width_percent=”100″ gutter_size=”3″ overlay_alpha=”50″ shift_x=”0″ shift_y=”0″ shift_y_down=”0″ z_index=”0″ medium_width=”0″ mobile_width=”0″ width=”1\/1″][vc_custom_heading heading_semantic=”h1″ text_size=”h1″]<\/p>\n

Which Drug Therapy for CLL, Time-Limited or Continuous?<\/h1>\n

<\/h2>\n

[\/vc_custom_heading][vc_column_text]This article was originally published by Medscape<\/a><\/p>\n

About two thirds of patients who are diagnosed with\u00a0chronic lymphocytic leukemia<\/a>\u00a0(CLL) are initially managed with a ‘watch-and-wait’ approach, but other one third of patients will need to be started on drug therapy straight away. But with which regimen?<\/p>\n

The standard therapy to date has been time-limited chemoimmunotherapy, and this still has a key role to play in certain cases. But evolving continuous treatments and evidence on the array of factors that can influence response are making decision-making more individualized than ever, said Matthew S. Davids, MD, MMSc, director of clinical research in the Division of\u00a0Lymphoma<\/a>\u00a0at Dana-Farber Cancer Institute and associate professor of medicine at Harvard Medical School, Boston, Massachusetts.<\/p>\n

“Continuous versus time-limited treatment discussions are long discussions now and should be individualized to particular patients and their comorbidities,” said Davids.<\/p>\n

<\/div>\n

Davids was speaking at a “How I Treat” session at the recent American Society of Hematology’s (ASH) Meeting on Hematological Malignancies, which was held virtually because of the COVID-19 pandemic.<\/p>\n

Key Factors to Consider<\/b><\/h3>\n

Key factors in determining the most effective approach are the patient’s\u00a0TP53<\/em>\u00a0and immunoglobulin heavy chain (IGHV) gene mutation status, Davids said.<\/p>\n

For instance, the traditional choice for frontline care for CLL has been standard chemoimmunotherapy (eg,\u00a0fludarabine<\/a>,\u00a0cyclophosphamide<\/a>\u00a0and\u00a0rituximab<\/a>\u00a0[FCR]), with a typical treatment duration of 6 months. However, the response effects appear most durable in younger patients with mutated IGHV and intact\u00a0TP53<\/em>.<\/p>\n

As evidence, Davids cited data from a\u00a0long-term follow-up<\/a>\u00a0of one of the original FCR studies in 300 patients, which found that about 60% of patients had long-term disease-free survival.<\/p>\n

To continue reading this article on Medscape<\/a>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

About two thirds of patients who are diagnosed with chronic lymphocytic leukemia (CLL) are initially managed with a ‘watch-and-wait’ approach,<\/p>\n","protected":false},"author":1,"featured_media":2016,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[17,23],"tags":[],"class_list":["post-14728","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-featured","category-research"],"jetpack_featured_media_url":"https:\/\/clladvocates.nz\/wp-content\/uploads\/2020\/07\/Matthew-DavidsMDMMsc.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/14728","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14728"}],"version-history":[{"count":1,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/14728\/revisions"}],"predecessor-version":[{"id":14729,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/14728\/revisions\/14729"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/media\/2016"}],"wp:attachment":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14728"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14728"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14728"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}